Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.07) by 457.14 percent. This is a 180.65 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $12.702 million which beat the analyst consensus estimate of $4.367 million by 190.89 percent. This is a 145.35 percent increase over sales of $5.177 million the same period last year.